In the high stakes world of life sciences, the strength of a company’s IP portfolio can determine the value of a corporate transaction, argue Jonathan Harris and Nisan Zaghi of Axinn, and Ian Lodovice of Biogen.
As opportunistic price-gougers look to capitalise on the COVID-19 pandemic, brands such as 3M have turned to trademark law to try and stop them. Brian Michalek and Erin Westbrook of Saul Ewing Arnstein & Lehr report.
Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
Foreign patents protecting COVID-19 treatments may stall efforts to protect citizens, says Mark Engelman of Hardwicke chambers.
Jonathan Tietz, Jason Mock, and Kristel Schorr of Foley & Lardner offer their thoughts on patent procurement and licensing for COVID-19-related technologies.
The Annual Summit on Life Sciences IP Due Diligence to be held on November 14 and 15 in Boston, MA, is a one-of-a-kind, interactive forum where diligence experts discuss best practices and strategies for executing a proper IP due diligence analysis for incumbent portfolios and those of potential targets.
Tensions between public use, drug laws and regulators make IP around Cannabis a complex situation, explains Ludmila Kawakami and Ana Paula D. C. Couto of Di Blasi, Parente & Associados.
LSX World Congress USA brings life sciences investment and partnering to Boston.
While providing benefits to Mexico’s biologics system, the USMCA may also increase costs for citizens, argues Margarita Guerrero Gonzalez of Uhthoff, Gomez Vega & Uhthoff.
Filing a divisional patent application in Brazil needs a keen understanding of the process and flexibility in the system, as Kene Gallois and Luis Felipe Maciel da Silva of Daniel Law explain.